Condition: Autism Spectrum Disorder · Sponsor: Stanford University
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.
This description comes directly from the study's public registry record.
Ramy Chebbo · (650) 723-7845 · autismresearch@stanford.edu
John Hegarty, PhD · (650) 723-7845 · hegartyj@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University School of Medicine | Stanford, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04278898